Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial
Abstract
(Abstracted from Lancet Oncol 2020;21:1661–1672) Standard-of-care treatment for stages III and IV newly diagnosed ovarian cancer involves primary debulking surgery followed by adjuvant paclitaxel and carboplatin or neoadjuvant chemotherapy with interval debulking surgery. Despite this protocol commonly resulting in complete remission, approximately 75% of patients will relapse within 2...
Paper Details
Title
Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial
Published Date
Mar 1, 2021
Volume
76
Issue
3
Pages
151 - 152
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History